IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation

Carcinogenesis

Volumn 35, Issue 5, 2014, Pages 1132-1143

  Massimino, Michele ^a   Consoli, Maria Letizia ^a   Mesuraca, Maria ^b   Stagno, Fabio ^a   Tirrò, Elena ^a   Stella, Stefania ^a   Pennisi, Maria Stella ^a   Romano, Chiara ^a   Buffa, Pietro ^a,c   Bond, Heather M ^b   Morrone, Giovanni ^b   Sciacca, Laura ^a   Di Raimondo, Francesco ^a   Manzella, Livia ^a   Vigneri, Paolo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; BCR ABL PROTEIN; CD34 ANTIGEN; IMATINIB; INTERFERON REGULATORY FACTOR 5; TYROSINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE CHECKPOINT; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LETHALITY; MUTANT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

BENZAMIDES; CATALYSIS; CELL LINE, TUMOR; CELL PROLIFERATION; ETOPOSIDE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHOSPHORYLATION; PIPERAZINES; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR STEM CELL ASSAY;

EID: 84901998145     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu013     Document Type: Article

References (46)

1. Cheng, T.F. et al. (2006) Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection. J. Immunol., 176, 7462-7470.
2. Tanaka, N. et al. (2000) The interferon regulatory factors and oncogenesis. Semin. Cancer Biol., 10, 73-81.
3. Lohoff, M. et al. (2005) Roles of interferon-regulatory factors in T-helpercell differentiation. Nat. Rev. Immunol., 5, 125-135.
4. Barnes, B.J. et al. (2001) Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J. Biol. Chem., 276, 23382-23390.
5. Lazear, H.M. et al. (2013) IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog., 9, e1003118.
6. Couzinet, A. et al. (2008) A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis. Proc. Natl Acad. Sci. USA, 105, 2556-2561.
7. Hu, G. et al. (2009) IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway. J. Biol. Chem., 284, 2767-2777.
8. Barnes, B.J. et al. (2003) Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res., 63, 6424-6431.
9. Li, Q. et al. (2008) Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts. Mol. Cancer Res., 6, 770-784.
10. Chen, W. et al. (2008) Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5. Nat. Struct. Mol. Biol., 15, 1213-1220.
11. Chang Foreman, H.C. et al. (2012) Activation of interferon regulatory factor 5 by site specific phosphorylation. PLoS One, 7, e33098.
12. Jo, S.H. et al. (2012) IRF-4 suppresses BCR/ABL transformation of myeloid cells in a DNA binding-independent manner. J. Biol. Chem., 287, 1770-1778.
13. Tamura, T. et al. (2003) ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood, 102, 4547-4554.
14. Melo, J.V., et al. (2003) Chronic myeloid leukemia. Hematology/the Education Program of the American Society of Hematology. Education Program, pp. 132-152.
15. Ren, R. (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer, 5, 172-183.
16. Stella, S. et al. (2013) Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. Mol. Cancer Ther., 12, 1085-1098.
17. Hantschel, O. et al. (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol., 5, 33-44.
18. Van Etten, R.A. (2002) Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene, 21, 8643-8651.
19. Hantschel, O. et al. (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat. Chem. Biol., 8, 285-293.
20. Skorski, T. et al. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J., 16, 6151-6161.
21. O'Hare, T. et al. (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 16, 401-412.
22. Weisberg, E. et al. (2007) Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer, 7, 345-356.
23. Rosti, G. et al. (2004) Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood, 103, 2284-2290.
24. Preisinger, C. et al. (2013) Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells. Leukemia, 27, 743-746.
25. Preyer, M. et al. (2011) Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. PLoS One, 6, e17020.
26. Kutner, R.H. et al. (2009) Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat. Protoc., 4, 495-505.
27. de Jong, R. et al. (1997) Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. Oncogene, 14, 507-513.
28. Griswold, I.J. et al. (2006) Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell. Biol., 26, 6082-6093.
29. Aloisi, A. et al. (2006) BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. Blood, 107, 1591-1598.
30. Ubersax, J.A. et al. (2007) Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell Biol., 8, 530-541.
31. Hu, G. et al. (2005) Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death. Cancer Res., 65, 7403-7412.
32. Fruehauf, S. et al. (2007) Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer, 109, 1543-1549.
33. Hughes, T.P. et al. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med., 349, 1423-1432.
34. Burchert, A. et al. (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J. Clin. Oncol., 28, 1429-1435
35. Bi, X. et al. (2011) Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res., 13, R111.
36. Mori, T. et al. (2002) Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene, 21, 2914-2918.
37. Massimino, M. et al. (2012) IRF5 promotes the proliferation of human thyroid cancer cells. Mol. Cancer, 11, 21.
38. Schmidt, M. et al. (2001) Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood, 97, 3648-3650.
39. Sattler, M. et al. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell, 1, 479-492.
40. Scherr, M. et al. (2006) Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood, 107, 3279-3287.
41. Holtschke, T. et al. (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell, 87, 307-317.
42. Burchert, A. et al. (2004) Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood, 103, 3480-3489.
43. Konieczna, I. et al. (2008) Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia. J. Clin. Invest., 284, 2549-2567.
44. Chen, B. et al. (2012) BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One, 7, e42598.
45. Guan, K.L. et al. (2000) Negative regulation of the serine/threonine kinase B-Raf by Akt. J. Biol. Chem., 275, 27354-27359.
46. De Roock, W. et al. (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol., 12, 594-603.